The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.
 
Antoni Ribas
Leadership - Arcus Biosciences; Lutris; PACT Pharma
Stock and Other Ownership Interests - 4c Biomed; Advaxis; Appia Bio; Arcus Biosciences; Compugen; CytomX Therapeutics; Highlight Therapeutics; ImaginAb; ImmPACT-Bio; Inspirna; Isoplexis; Kite/Gilead; Lutris; MapKure; Merus; PACT Pharma; Pluto Immunotherapeutics; RAPT Therapeutics; Synthekine; Tango Therapeutics
Honoraria - Amgen; AstraZeneca; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi; Vedanta Biosciences
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Non-viral gene editing to Arsenal Bio
 
Pier Francesco Ferrucci
Expert Testimony - Delcath Systems
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre; Provectus Biopharmaceuticals; QBiotics; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; QBiotics; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Expert Testimony - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec; Pierre Fabre
 
Rosalie Stephens
Consulting or Advisory Role - GlaxoSmithKline
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics
 
Donald P. Lawrence
No Relationships to Disclose
 
Michele Del Vecchio
Consulting or Advisory Role - Bristol Myers Squibb; Merck; Novartis; Pierre Fabre
 
Omid Hamid
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Alkermes; Amgen; BeiGene; BioAtla; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Idera; Immunocore; Incyte; Iovance Biotherapeutics; Janssen; Merck; NextCure; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Henrik Schmidt
Research Funding - MSD
 
Jacob Schachter
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - MSD
 
Paola Queirolo
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma Advanced Research Company
Travel, Accommodations, Expenses - MSD Oncology; Sanofi/Regeneron
 
Wilson H. Miller
Honoraria - Amgen; Bristol Myers Squibb Foundation; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche; Sanofi; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Merck; Mylan; Novartis; Roche; Sanofi
Research Funding - Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Canada Research Society (Inst); Canadian Cancer Society Research Institute (CCSRI) (Inst); Canadian Institutes of Health Research (CIHR) (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); MethylGene (Inst); Mimic Technologies (Inst); Novartis (Inst); Ocellaris Pharma (Inst); Pfizer (Inst); Roche (Inst); Samuel Waxman Cancer Research Foundation (Inst); Sanofi (Inst); TERRY FOX RESEARCH INSTITUTE (Inst)
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Merck Serono; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Anna Maria Di Giacomo
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Pierre Fabre; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Inge Marie Svane
Stock and Other Ownership Interests - IO Biotech
Honoraria - BMS; IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; Sanofi/Aventis; TILT Biotherapeutics
Consulting or Advisory Role - IO Biotech; MSD; Novartis; Novo Nordisk; Pierre Fabre; TILT Biotherapeutics
Research Funding - Adaptimmune (Inst); Bristol-Myers Squibb (Inst); IO Biotech (Inst); Lytix Biopharma (Inst); TILT Biotherapeutics (Inst)
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer
 
Razi Ghori
Employment - Merck
 
Rohini Singh
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
 
Scott J. Diede
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - 4SC; Alkermes; Array BioPharma; AstraZeneca; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Incyte; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Takis Biotech; Ultimovacs
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme